A Phase 1/2 trial of the TGFB2-specific antisense oligonucleotide trabedersen in patients with various solid tumors, including colorectal carcinoma, melanoma or pancreatic cancer, has reported that the treatment was safe and well tolerated, though further efficacy studies are pending. The gene discussed is TGFB2; the disease is pancreatic neoplasm.